<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> and excessive body fat are considered principal causes of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (a metaplastic change in the cells lining the oesophagus) and its <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e>, oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Metabolic disturbances including altered levels of <z:hpo ids='HP_0001513'>obesity</z:hpo>-related cytokines, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> have also been associated with <z:e sem="disease" ids="C0546837" disease_type="Neoplastic Process" abbrv="">oesophageal cancer</z:e> development, especially in males </plain></SENT>
<SENT sid="2" pm="."><plain>Physical activity may have the potential to abrogate metabolic disturbances in males with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and elicit beneficial reductions in body fat and <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux</z:e> symptoms </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, exercise may be an effective intervention in reducing oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> risk </plain></SENT>
<SENT sid="4" pm="."><plain>However, to date this hypothesis remains untested.The 'Exercise and the Prevention of <z:e sem="disease" ids="C0546837" disease_type="Neoplastic Process" abbrv="">Oesophageal Cancer</z:e> Study' will determine whether 24 weeks of exercise training will lead to alterations in risk factors or biomarkers for oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in males with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Our primary outcomes are serum concentrations of leptin, adiponectin, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha, C-reactive protein and interleukin-6 as well as <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Body composition, <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> symptoms, cardiovascular fitness and muscular strength will also be assessed as secondary outcomes </plain></SENT>
<SENT sid="7" pm="."><plain>METHODS/DESIGN: A randomized controlled trial of 80 overweight or <z:mp ids='MP_0001261'>obese</z:mp>, inactive males with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> will be conducted in Brisbane, Australia </plain></SENT>
<SENT sid="8" pm="."><plain>Participants will be randomized to an intervention arm (60 minutes of moderate-intensity aerobic and resistance training, five days per week) or a control arm (45 minutes of stretching, five days per week) for 24 weeks </plain></SENT>
<SENT sid="9" pm="."><plain>Primary and secondary endpoints will be measured at baseline (week 0), midpoint (week 12) and at the end of the intervention (week 24) </plain></SENT>
<SENT sid="10" pm="."><plain>DISCUSSION: Due to the increasing incidence and very high mortality associated with oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, interventions effective in preventing the progression of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> are urgently needed </plain></SENT>
<SENT sid="11" pm="."><plain>We propose that exercise may be successful in reducing oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> risk </plain></SENT>
<SENT sid="12" pm="."><plain>This primary prevention trial will also provide information on whether the protective association between physical activity and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is causal </plain></SENT>
<SENT sid="13" pm="."><plain>TRIAL REGISTRATION: ACTRN12609000401257 </plain></SENT>
</text></document>